Full year 2024 financial guidance is reiterated and consists of the following: Combined net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO1 $1,575 million – $1,650 million; Net Product Revenue Growth vs. 2023 at reported FX rates1 27% to 33%; Net Product Revenue Growth vs. 2023 at CER 28% to 34% Net revenues from collaborations and royalties $575 million – $650 million..
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALNY:
- Alnylam reports Q3 EPS (50c), consensus (93c)
- ALNY Earnings this Week: How Will it Perform?
- Alnylam price target raised to $371 from $282 at TD Cowen
- Disney initiated, Cisco upgraded: Wall Street’s top analyst calls
- Alnylam submits regulatory application to EMA for vutrisiran for ATTR-CM
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
